Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ATP4A | P20648 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
| ▸ | ATP4B | P51164 | 1/20 | 0.32 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 0.32 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9286732 | 0.97 | CYP2C9 (0.38) | CYP2C9EPHX2KDM4EMAPTLMNA | |
| SCHEMBL9529094 | 0.93 | CYP2C9 (0.34) | CYP2C9EPHX2KDM4EMAPTLMNA | |
| SCHEMBL9530345 | 0.90 | CYP2C9 (0.34) | CYP2C9KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL9544128 | 0.89 | CYP2C9 (0.41) | CYP2C9EPHX2KDM4EMAPTLMNA | |
| SCHEMBL9541724 | 0.88 | CYP2C9 (0.41) | CYP2C9EPHX2KDM4EMAPTLMNA | |
| SCHEMBL9532433 | 0.88 | CYP2C9 (0.32) | CYP2C9EPHX2KDM4EMAPTLMNA | |
| SCHEMBL9755547 | 0.87 | CYP2C9 (0.41) | CYP2C9KDM4EMAPTLMNAALDH1A1 | |
| SCHEMBL9231523 | 0.87 | CYP2C9 (0.36) | CYP2C9EPHX2KDM4EMAPTLMNA | |
| SCHEMBL9232189 | 0.87 | CYP2C9 (0.36) | CYP2C9EPHX2KDM4EMAPTLMNA | |
| SCHEMBL9232184 | 0.87 | CYP2C9 (0.36) | CYP2C9EPHX2KDM4EMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| WO-1996016959-A1 | A PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1996-06-06 | — | — | WO | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| WO-1991019711-A1 | SUBSTITUTED BENZIMIDAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | AKTIEBOLAGET ASTRA (SE) | 1991-12-26 | — | — | WO | claimed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1996016959-A1 | A PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1996-06-06 | — | — | WO | disclosed |
| WO-1996016959-A1 | A PROCESS FOR THE PREPARATION OF BENZIMIDAZOLE DERIVATIVES | ASTRA AKTIEBOLAG (SE) | 1996-06-06 | — | — | WO | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| WO-1995015962-A1 | SUBSTITUTED BENZIMIDAZOLE, PROCESSES FOR ITS PREPARATION AND ITS PHARMACEUTICAL USE | ASTRA AKTIEBOLAG (SE) | 1995-06-15 | — | — | WO | disclosed |
| WO-1991019711-A1 | SUBSTITUTED BENZIMIDAZOLES, PROCESS FOR THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | AKTIEBOLAGET ASTRA (SE) | 1991-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | CYP2C9 1120/4885EPHX2 2387/4885KDM4E 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.